Jump to content

UWA-001

From Wikipedia, the free encyclopedia
UWA-001
Identifiers
  • 2-(1,3-benzodioxol-5-yl)-N-methyl-1-phenylethanamine
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC16H17NO2
Molar mass255.317g·mol−1
3D model (JSmol)
  • CNC(Cc1ccc2OCOc2c1)c3ccccc3
  • InChI=1S/C16H17NO2/c1-17-14(13-5-3-2-4-6-13)9-12-7-8-15-16(10-12)19-11-18-15/h2-8,10,14,17H,9,11H2,1H3
  • Key:DNOTUUOUOFJQJC-UHFFFAOYSA-N

UWA-001(also known asα-phenyl-MDMAandmethylenedioxymephenidine) is aphenethylaminederivative invented at theUniversity of Western Australiaas non-toxic alternative to3,4-methylenedioxy-N-methylamphetamine(MDMA) and researched as a potential treatment forParkinson's disease.[1]

It has a5-HT2Areceptoraffinity of 1.2 μM (~10-fold increase compared to MDMA), 1.3 μM for theserotonin transporter(~4-fold decrease compared to MDMA), 13.4 μM for thenorepinephrine transporter(~26-fold increase compared to MDMA) and virtually no affinity for thedopamine transporter(>50 μM).[1]

Unlike MDMA andpara-methoxyamphetamine(but similarly toketamine),[2]UWA-001 increasesprepulse inhibitionand was therefore considered to be non-psychoactive, though it was not assayed at other binding sites.[3]It is toxic to theSH-SY5Ycell line at high concentrations, however significantly less toxic than MDMA at all concentrations tested.[3]

UWA-001 is structurally related to the diarylethylamineslefetamine(astimulantandopioid) and thedissociativeanestheticephenidine,which acts as aNMDA receptor antagonist.

See also[edit]

References[edit]

  1. ^abJohnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, et al. (May 2012)."A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates".FASEB Journal.26(5): 2154–63.doi:10.1096/fj.11-195016.PMID22345403.S2CID37589231.
  2. ^Abel KM, Allin MP, Hemsley DR, Geyer MA (May 2003). "Low dose ketamine increases prepulse inhibition in healthy men".Neuropharmacology.44(6): 729–37.doi:10.1016/S0028-3908(03)00073-X.PMID12681371.S2CID25706718.
  3. ^abGandy MN, McIldowie M, Lewis K, Wasik AM, Salomonczyk D, Wagg K, et al. (2010). "Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity".MedChemComm.1(4): 287–93.doi:10.1039/C0MD00108B.